Serina Therapeutics delivered a typical pre-revenue biotech QQ4 2024 result profile, characterized by no reported revenue and a material operating loss driven by ongoing R&D and G&A spending. The company reported R&D expenses of $2.365 million and general and administrative expenses of $3.170 million, culminating in total operating expenses of $5.549 million and an EBITDA of $(2.679) million for the quarter. Net income came in at $(2.74) million with basic EPS of $(0.31) and diluted EPS of $(0.25). The quarter did not include revenue, underscoring the company’s early-stage clinical/preclinical phase and reliance on external financing to fund ongoing development.
Key Performance Indicators
Operating Income
Decreasing
-5.55M
QoQ: -4.46% | YoY: -55.87%
Net Income
Increasing
-2.74M
QoQ: -294.33% | YoY: 20.72%
EPS
Increasing
-0.31
QoQ: -293.75% | YoY: 90.31%
Revenue Trend
Margin Analysis
Financial Highlights
Revenue: N/A for QQ4 2024; Gross Profit: N/A; Operating Income: $(5.549) million for Q4 2024; EBITDA: $(2.679) million; Net Income: $(2.74) million; EPS (basic/diluted): $(0.31)/$(0.25); R&D expense: $2.365 million; G&A expense: $3.170 million; Depreciation & Amortization: $0.056 million; Interest expense: $0.017 million; Cash at period end: $3.672 million; Net cash from operating activities: $(4.589) million; Free cash flow: $(4.594) million; Cash burn and negative operating cash flow indicate a near-term reliance on financing; Current ratio: 2.40x; Cash ratio: 1.55x; Debt: $0.268 million (long-term); Net debt: $(3.404) million indicating net cash position; Total assets: $6.724 million; Total liabilities: $6.216 million; Stockholders’ equity: $0.641 million (note: accumulated deficit and other equity lines contribute to a nuanced balance sheet).
Income Statement
Metric
Value
YoY Change
QoQ Change
Operating Income
-5.55M
-55.87%
-4.46%
Net Income
-2.74M
20.72%
-294.33%
EPS
-0.31
90.31%
-293.75%
Key Financial Ratios
Return on Assets
Weak
-0.41%
Return on assets suggests inefficient capital allocation
Return on Equity
Weak
-4.27%
Return on equity suggests inefficient capital allocation
Current Ratio
Healthy
2.40
Current ratio shows adequate liquidity to meet short-term obligations
Debt to Equity
Moderate
0.42
Debt-to-equity indicates balanced capital structure with manageable debt
P/E Ratio
Negative
-4.05x
Negative earnings make P/E ratio not meaningful
Price to Book
High Premium
69.18x
Very high premium suggests asset-light business model or lofty expectations
Management Insights Available for Members
Get exclusive access to management commentary, earnings call quotes, and forward guidance from company leadership.